SCHEMBL3859809

SCHEMBL3859809

CCC(=O)C=Cc1ccc(O)c(OC)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.83
MAPT P10636 5/20 0.83
NFKB1 P19838 4/20 0.83
CYP2D6 P10635 3/20 0.83
MAOB P27338 3/20 0.83
BACE1 P56817 3/20 0.83
ALOX5 P09917 3/20 0.83
STAT3 P40763 3/20 0.83
NFKB2 Q00653 3/20 0.83
RELA Q04206 3/20 0.83
MMP9 P14780 3/20 0.83
CYP2C9 P11712 2/20 0.83
TSHR P16473 2/20 0.83
HSD17B10 Q99714 2/20 0.83
ABCB1 P08183 2/20 0.83
AKR1B1 P15121 2/20 0.83
MAOA P21397 2/20 0.83
CYP1A2 P05177 2/20 0.83
HSD11B1 P28845 2/20 0.83
NFE2L2 Q16236 2/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3859807 1.00 APP (0.83) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL8336603 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL250984 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL29355906 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL2804734 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL17629819 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL8440 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL17629818 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL6901740 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB
Curcumin SCHEMBL29876635 0.91 APP (1.00) APPMAPTNFKB1CYP2D6MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011293-A1 LEUKOTRIENE SYNTHESIS INHIBITORS NAEGIS PHARMACEUTICALS INC. (CA) 2025-01-09 US disclosed
US-11976052-B2 Leukotriene synthesis inhibitors NAEGIS PHARMACEUTICALS INC. (CA) 2024-05-07 US disclosed
US-20220064132-A1 LEUKOTRIENE SYNTHESIS INHIBITORS NAEGIS PHARMACEUTICALS INC. (CA) 2022-03-03 US disclosed
CN-113784713-A Leukotriene synthesis inhibitors 纳吉斯制药股份有限公司 2021-12-10 CN disclosed
US-7589123-B2 Chemical compounds PHYTOPHARM PLC (GB) 2009-09-15 US disclosed
CN-101511350-A Dioxo-alkanes and dioxo-alkenes PHYTOPHARM PLC (GB) 2009-08-19 CN disclosed
EP-2046311-A2 DIOXO-ALKANES AND DIOXO-ALKENES Phytopharm Plc (GB) 2009-04-15 EP disclosed
US-20080045591-A1 Chemical Compounds VECTURA LIMITED (GB) 2008-02-21 US disclosed
WO-2008003978-A2 DIOXO-ALKANES AND DIOXO-ALKENES PHYTOPHARM PLC (GB) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064132-A1 LEUKOTRIENE SYNTHESIS INHIBITORS LTC4S, LTB4R2, LTA4H APP 1371/4885MAPT 3739/4885NFKB1 472/4885
US-20080045591-A1 Chemical Compounds CYP11B1, CYP11B2, CYP2S1 APP 912/4885MAPT 1646/4885NFKB1 1509/4885
US-11976052-B2 Leukotriene synthesis inhibitors LTC4S, LTB4R2, LTA4H APP 1371/4885MAPT 3739/4885NFKB1 472/4885
US-20250011293-A1 LEUKOTRIENE SYNTHESIS INHIBITORS LTC4S, LTB4R2, LTA4H APP 1371/4885MAPT 3739/4885NFKB1 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.